CD274 and neoplasm: Modern immunomodulatory therapeutic strategies have targeted the PD-1/PD-L1 axis, and different systems have been developed to evaluate and grade the immunohistochemical expression of PDL-1 in different tumor types, with the latter being considered the most reliable therapeutic predictive marker for response to immunotherapy [21,22].